Position in COLL
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$605,951
-$287,898 QoQ
Shares Held
16,739
-38.1% QoQ
Ownership
0.051%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#132
of 277 holders
Holding Since
Dec 2022
9 quarters on record
Voting authority
Sole 2%
Shared 0%
None 98%
Common Shares in COLL Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026NewEdge Advisors, LLC holds $12,323,215 across 27 Drug Manufacturers - Specialty & Generic names. COLL ranks #8 (4.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZTS |
Zoetis Inc.
|
36,078 | $2,592,565 | |
| 2 | NBIX |
Neurocrine Biosciences Inc
|
12,619 | $2,126,806 | |
| 3 | UTHR |
UNITED THERAPEUTICS Corp
|
3,861 | $2,092,005 | |
| 4 | TEVA |
Teva Pharmaceutical Industries Ltd
|
37,994 | $1,287,236 | |
| 5 | HLN |
Haleon plc
|
133,508 | $1,245,629 | |
| 6 | HIMS |
Hims & Hers Health, Inc.
|
21,721 | $753,067 | |
| 7 | VTRS |
Viatris Inc
|
39,976 | $634,818 | |
| 8 | COLL |
Collegium Pharmaceutical, Inc
This page
|
16,739 | $605,951 |
All Filings in COLL
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $605,951 | 16,739 | Shares | Sole | 2026-08-12 | |
| 2026-03-31 | $893,849 | 27,029 | Shares | Sole | 2026-06-03 | |
| 2025-12-31 | $587,130 | 12,681 | Shares | Sole | 2026-02-18 | |
| 2025-09-30 | $677,966 | 19,376 | Shares | Sole | 2025-11-17 | |
| 2025-06-30 | $90,099 | 3,047 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $22,477 | 753 | Shares | Sole | 2025-05-15 | |
| 2023-06-30 | $2,922 | 136 | Shares | Sole | 2023-08-14 | |
| 2023-03-31 | $5,205 | 217 | Shares | Sole | 2023-05-12 | |
| 2022-12-31 | $42,641 | 1,838 | Shares | Sole | 2023-02-14 | |
| No filing history on record for this holder in this stock. | ||||||